Bruker (BRKR) Income from Continuing Operations (2010 - 2026)
Bruker's (BRKR) quarterly Income from Continuing Operations came in at -$65.2 million in Q2 2026, down 816.48% on a YoY basis from $9.1 million in Q2 2025, and down 605.43% quarter-over-quarter from $12.9 million in Q1 2026.
Analysis
Bruker (BRKR) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Bruker (BRKR) has reported Income from Continuing Operations for 17 consecutive years, with -$65.2 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations fell 816.48% year-over-year to -$65.2 million; the trailing twelve-month figure through Jun 2026 stood at $133.9 million (down 48.46% YoY), and the FY2025 full-year result was $206.2 million, down 31.7% from the prior year.
- Income from Continuing Operations retreated to -$65.2 million in Q2 2026 per BRKR's latest filing, from $12.9 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $243.9 million in Q4 2025 and bottomed at -$72.1 million in Q1 2024.
- Historically, Income from Continuing Operations has averaged $49.9 million across 5 years, with a median of $34.2 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 137.92% in 2025, then slumped 816.48% in 2026.
- Over 5 years, Income from Continuing Operations stood at $99.9 million in 2022, then soared by 78.28% to $178.1 million in 2023, then grew by 13.31% to $201.8 million in 2024, then advanced by 20.86% to $243.9 million in 2025, then tumbled by 126.73% to -$65.2 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered -$65.2 million, $12.9 million, and $243.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 224.92 Bn | 220.86 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 144.28 Bn | 139.93 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Agilent Technologies | 40.97 Bn | 39.21 Bn | 1.04 Bn | 362.00 Mn |
| 4 | Illumina | 31.40 Bn | 30.23 Bn | 770.00 Mn | 207.00 Mn |
| 5 | Revvity | 13.71 Bn | 12.68 Bn | 416.87 Mn | 53.48 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 54.62 Mn |
| 7 | Bio-Rad Laboratories | 10.08 Bn | 8.46 Bn | 345.80 Mn | 371.40 Mn |
| 8 | Repligen | 9.47 Bn | 8.46 Bn | 110.04 Mn | 5.01 Mn |
| 9 | 10x Genomics | 8.71 Bn | 8.16 Bn | 112.50 Mn | -17.93 Mn |
| 10 | Bruker | 8.37 Bn | 8.16 Bn | 416.00 Mn | -65.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -65.20 Mn |
| Mar 31, 2026 | 12.90 Mn |
| Dec 31, 2025 | 243.90 Mn |
| Sep 30, 2025 | -57.70 Mn |
| Jun 30, 2025 | 9.10 Mn |
| Mar 31, 2025 | 8.40 Mn |
| Dec 31, 2024 | 201.80 Mn |
| Sep 30, 2024 | 40.50 Mn |
| Jun 30, 2024 | -24.00 Mn |
| Mar 31, 2024 | -72.10 Mn |
| Dec 31, 2023 | 178.10 Mn |
| Sep 30, 2023 | 88.40 Mn |
| Jun 30, 2023 | 38.30 Mn |
| Mar 31, 2023 | 47.60 Mn |
| Dec 31, 2022 | 99.90 Mn |
| Sep 30, 2022 | 88.10 Mn |
| Jun 30, 2022 | 30.00 Mn |
| Mar 31, 2022 | 30.20 Mn |
| Dec 31, 2021 | 84.20 Mn |
| Sep 30, 2021 | 88.10 Mn |